Dr. Macarena de la Fuente (IMAGE)

Public Relations Pacific LLC

Dr. Macarena de la Fuente

Caption

“Our study, which included adults and children with advanced, solid tumors that could not be surgically removed, showed promising activity against V600 and non-V600 BRAF mutant tumors, including primary central nervous system (CNS) tumors,” said Dr. Macarena de la Fuente, chief of Neuro-Oncology at Sylvester Comprehensive Cancer Center, whose research focuses on developing treatments for primary brain tumors.

Credit

Sylvester Comprehensive Cancer Center

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.